Advertisement

 

 

Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.

Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.
Author Information (click to view)

Gurka MJ, Guo Y, Filipp SL, DeBoer MD,


Gurka MJ, Guo Y, Filipp SL, DeBoer MD, (click to view)

Gurka MJ, Guo Y, Filipp SL, DeBoer MD,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Cardiovascular diabetology 2018 01 1917(1) 17 doi 10.1186/s12933-017-0647-y
Abstract
BACKGROUND
The severity of the metabolic syndrome (MetS) is significantly associated with future coronary heart disease (CHD) among individuals without baseline Type 2 diabetes. However, the validity of assessing MetS severity among individuals with diabetes is unknown.

OBJECTIVE
To assess for differences in MetS severity by timing of Type 2 diabetes diagnosis and to assess for associations between MetS severity and future CHD among individuals with diabetes.

METHODS
We analyzed data from participants of the Atherosclerosis Risk in Communities study, including 1419 with- and 7241 without diabetes, followed during 4 visits and adjudicated CHD diagnoses over a 20-year period. We used Cox-regression techniques to assess hazard ratios (HR) of CHD based on a sex- and race/ethnicity-specific MetS-severity Z-score (standard MetS score) and a similar MetS-severity score formulated without incorporating glucose as a component of MetS (no-glucose MetS score).

RESULTS
For both the standard- and no-glucose MetS-severity scores, scores were highest in the baseline-diabetes group, lowest in the never-diabetes group and intermediate in the incident-diabetes groups. Among participants with diabetes, increasing MetS-severity score at baseline was associated with incident CHD, using both the standard MetS score (HR 1.29, 95% confidence interval [CI] 1.21, 1.39) and the no-glucose score (HR 1.42, CI 1.24, 1.62) (both p < 0.001). For the baseline-diabetes group, this relationship remained significant when Visit 2 Hemoglobin-A1c was included in the model, both for the standard MetS score (HR 1.21, CI 1.09, 1.34; p < 0.001) and the no-glucose score (HR 1.25, CI 1.04, 1.51; p = 0.02). CONCLUSIONS
MetS severity appears to provide an estimate of metabolic disarray in the setting of diabetes and is predictive of future CHD events beyond HbA1c. Identifying MetS severity among individuals with diabetes may help in identifying those at higher risk, who could then receive further preventative treatment.

Submit a Comment

Your email address will not be published. Required fields are marked *

four + 11 =

[ HIDE/SHOW ]